Phase 0 Microdose Study to Evaluate the Effect of Melphalan, Bortezomib and Dexamethasone on Cellular Gene-expression in Patients With Multiple Myeloma

Trial Profile

Phase 0 Microdose Study to Evaluate the Effect of Melphalan, Bortezomib and Dexamethasone on Cellular Gene-expression in Patients With Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Melphalan (Primary)
  • Indications Multiple myeloma
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 29 Jul 2016 This trial has been completed in Denmark (End date:2015-12-31) as per European Clinical Trials Database record.
    • 07 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Jul 2014 New source identified and integrated (European Clinical Trials Database - EudraCT2011-003791-37).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top